Funding
← Back to your selection

Frazier Life Sciences

Activity from announced rounds

Activity in this selectionOct 24, 2026 · Healthtech · Jan 1, 2026
Rounds participated in
2
Confirmed lead rounds
—
2 roles undisclosed
New companies
2
First participation on record · 0 follow-on
Funding in participating rounds
$245M
2 disclosed · full round size, not this investor’s share

By stage

Series A1
Series B1

By primary sector

Biotech2

By country

United Kingdom1
United States1

Rounds

2 in this selection
Crystalys Therapeutics

Crystalys Therapeutics develops dotinurad, an oral URAT1 inhibitor for treating gout

$130MSeries B
Role not disclosed
RQ Bio

Develops antibody therapies to prevent seasonal influenza in high-risk and immunocompromised patients

$115MSeries A
Role not disclosed